The paradox of Myeloid Leukemia associated with Down syndrome.
Gupte A, Al-Antary ET, Edwards H, Ravindranath Y, Ge Y, Taub JW.
Biochem Pharmacol. 2022 Jul;201:115046. doi: 10.1016/j.bcp.2022.115046. Epub 2022 Apr 26.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW.
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
Management of Down Syndrome-Associated Leukemias: A Review.
Verma A, Lupo PJ, Shah NN, Hitzler J, Rabin KR.
JAMA Oncol. 2023 Sep 1;9(9):1283-1290. doi: 10.1001/jamaoncol.2023.2163.
The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR.
Virchows Arch. 2023 Jan;482(1):113-130. doi: 10.1007/s00428-022-03447-9. Epub 2022 Nov 29.
Neonatal Leukemia.
Brown PA.
Clin Perinatol. 2021 Mar;48(1):15-33. doi: 10.1016/j.clp.2020.11.002.
Advances in molecular characterization of myeloid proliferations associated with Down syndrome.
Li J, Kalev-Zylinska ML.
Front Genet. 2022 Aug 10;13:891214. doi: 10.3389/fgene.2022.891214. eCollection 2022.
Neonatal leukaemia.
Roberts I, Fordham NJ, Rao A, Bain BJ.
Br J Haematol. 2018 Jul;182(2):170-184. doi: 10.1111/bjh.15246. Epub 2018 May 28.
Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes.
de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, Obulkasim A, Dang J, Easton J, Verboon LJ, Mulder HL, Zimmermann M, Koss C, Gupta P, Edmonson M, Rusch M, Lim JY, Reinhardt K, Pigazzi M, Song G, Yeoh AE, Shih LY, Liang DC, Halene S, Krause DS, Zhang J, Downing JR, Locatelli F, Reinhardt D, van den Heuvel-Eibrink MM, Zwaan CM, Fornerod M, Gruber TA.
Nat Genet. 2017 Mar;49(3):451-456. doi: 10.1038/ng.3772. Epub 2017 Jan 23.
Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ): Health Professional Version.
PDQ Pediatric Treatment Editorial Board.
2024 Sep 16. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–.
Evolution of myeloid leukemia in children with Down syndrome.
Saida S.
Int J Hematol. 2016 Apr;103(4):365-72. doi: 10.1007/s12185-016-1959-5. Epub 2016 Feb 24.
